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Conventional chemotherapeutic agents are often toxic not only to tumor cells but also to
normal cells, limiting their therapeutic use in the clinic. Novel natural product anticancer
compounds present an attractive alternative to synthetic compounds, based on their favor-
able safety and efﬁcacy proﬁles. Several pre-clinical and clinical studies have demonstrated
the anticancer potential of Panax ginseng, a widely used traditional Chinese medicine.The
anti-tumor efﬁcacy of ginseng is attributed mainly to the presence of saponins, known as
ginsenosides. In this review, we focus on how ginsenosides exert their anticancer effects
by modulation of diverse signaling pathways, including regulation of cell proliferation medi-
ators (CDKs and cyclins), growth factors (c-myc, EGFR, and vascular endothelial growth
factor), tumor suppressors (p53 and p21), oncogenes (MDM2), cell death mediators (Bcl-
2, Bcl-xL, XIAP, caspases, and death receptors), inﬂammatory response molecules (NF-κB
and COX-2), and protein kinases (JNK, Akt, and AMP-activated protein kinase).We also dis-
cuss the structure–activity relationship of various ginsenosides and their potentials in the
treatment of various human cancers. In summary, recent advances in the discovery and
evaluation of ginsenosides as cancer therapeutic agents support further pre-clinical and
clinical development of these agents for the treatment of primary and metastatic tumors.
Keywords: Panax genus, Panax ginseng, ginsenosides, anticancer activities, structure–activity relationship,
molecular mechanism, pre-clinical pharmacology, clinical trials
INTRODUCTION
A BRIEF HISTORY OF GINSENG AND GINSENG PRODUCTS
Panax ginseng was discovered over 5000 years ago on the hills
of Manchuria in China and since then held its place as a highly
venerated medicinal plant in Traditional Chinese Medicine (Hem-
merly, 1977). The ancient Chinese used it for various health
beneﬁts, ranging from overcoming fatigue to treating severe car-
diac problems; ancient texts showed that ginseng was valued
more than gold and was often reserved for treatment of royalty.
The “Shennong Bencao Jing” written around 100 A.D. attributed
longevity boosting properties to ginseng and stated that it was
good for “enlightening the mind and increasing the wisdom”
(Dharmananda, 2002).
The discovery of an American counterpart for this “miracle”
plant happened in 1714,due to the efforts of Father Laﬁtau, a Jesuit
priest, working with the Iroquois in Canada. Based on the theory
that ginseng might grow wild in the Americas, due to a similar-
ity in climactic conditions with China, Father Laﬁtau undertook
a laborious search for the plant and eventually discovered that it
was used as a medicinal herb by the native Indians too (Yun, 2001;
Grafton, 2002). The British physicians F. Porter Smith and G. A.
Stuart, working in China at the end of the nineteenth century,
were among the ﬁrst to introduce the medicinal qualities of this
herb to aWestern audience (Dharmananda, 2002). The popularity
of ginseng in the western world grew as a “drug weary” popula-
tion medicated heavily on increasingly toxic chemical compounds
started to explore alternative and traditional forms of medicine.
Ginseng began to be sold in the form of liquid extracts, capsules,
chewing gum, teas, candy, and cigarettes. It was used for treating
rheumatism,anemia, insomnia, and various other problems. Some
even purchased ginseng products for their alleged aphrodisiac
properties. Ginseng fragranceswere incorporated in cosmetics and
soaps. By 1980s an estimated ﬁve to six million Americans were
routinely using ginseng products (Carlson, 1986). In fact, the sale
of ginseng products in the United States alone was estimated to
reach US$83 million in 2010.
In the early 1970s, reports, primarily from China and Korea,
started claiming that the herb stimulated protein synthesis, low-
ered blood sugar and cholesterol levels, regulated rate of metabo-
lism,protected against stress, and could therefore reducemortality.
Asiatic ginseng from eastern Siberia was reportedly used by Soviet
cosmonauts andOlympic team trainees to reduce fatigue (Carlson,
1986). During the same period, the Fromm Operation based in
Wisconsin funded research on the possibility of using compounds
from American ginseng in cancer research (Carlson, 1986). Since
then, ginseng’s usefulness in cancer has been shown by extensive
www.frontiersin.org February 2012 | Volume 3 | Article 25 | 1
Nag et al. Ginsenosides in cancer therapy
pre-clinical and epidemiological studies (Attele et al., 1999; Court,
2000; Bespalov et al., 2001; Yoo et al., 2006). It is also demon-
strated that prolonged oral administration of red ginseng extract
(RGE) to rats dosed with a carcinogen such as DMBA, urethane,
or aﬂatoxin B1, reduced the incidence and mass of tumors (Yun
et al., 1983). Additionally, red ginseng has been shown to improve
postoperative survival in patients with stage III gastric cancer (Suh
et al., 2002). There is an increasing interest in developing ginseng
products as anticancer agents, especially in combination therapy.
ETHNOBOTANY
The word Panax, ﬁrst used by the Russian botanist Carl Anton
Von Meyer, is derived from the Greek word meaning “all-healing”
(Court, 2000). On the other hand, the English word ginseng is
derived from the Chinese term “rénshen” which literally means
“man root”: a reference to the root’s resemblance to the legs of a
human.ThePanax genus belongs to the familyAraliaceae and con-
sists of at least nine species, including P. ginseng (Asian ginseng),
P. quinquefolium L. (Xiyangshen, American ginseng), P. notogin-
seng (Sanqi), and P. japonicas (Japanese ginseng; Lee and Zhao,
2009). Among them, P. ginseng is the most widely used ginseng
and is indigenous to the Far East countries, most notably China
and Korea. P. quinquefolium is indigenous to the United States
and Canada (Lee and Zhao, 2009). Out of these, P. ginseng C. A.
Meyer,P. quinquefolium L,andP. notoginseng havebeen extensively
investigated for their physiological and pharmacological effects on
human body.
Ginseng is a perennial herb,60–80 cm tall. Its root,often 5–6 cm
long, is ﬂeshy, bifurcate, aromatic, and grayish white to amber yel-
low. The surface of root is wrinkled and furrowed, and its taste is
sweetish at ﬁrst, with a somewhat bitter after taste. Ginseng stem is
simple, erect, and deep red; its ﬂower is pink; and its fruit, a small
berry, is red. The leaves are compound, digitate, oval, and thin.
There are a total of ﬁve leaﬂets and the three terminal leaﬂets are
larger than the two lateral ones (Yun, 2001; Coates et al., 2005).
CHEMICAL CONSTITUENTS OF PLANTS FROM THE GENUS
PANAX
In general, the active or inactive chemical entities obtained from
ginseng species can be classiﬁed into four categories as follows.
SAPONINS (OR SAPOGENIN GLYCOSIDES)
Saponins are glycosides consisting of a sapogenin moiety, which
may be a steroid or a triterpene, attached to one or more sugar
moieties. Ginseng saponins are generally called ginsenosides and
are the main active principals of ginseng. They are often used as
a marker for the quality control of ginseng drugs and commer-
cial products. For example, the ginsenoside Rf is unique to Asian
ginseng while F11 is found exclusively in American ginseng. Thus
the Rf/F11 ratio is used as a phytochemical marker to distinguish
American ginseng from Asian ginseng (Li et al., 2000; Assinwe
et al., 2003).
The basic structures of ginsenosides are similar, and most gin-
senosides consist of a dammarane steroid nucleus with 17 carbon
atoms arranged in four rings. Ginsenoside structures are ﬁrst elu-
cidated by the Shibata group, and named as Rx according to their
mobility on TLC plates, with polarity decreasing from index “a”
to “h” (Sanada et al., 1974; Liu and Xiao, 1992). According to a
Ginseng Evaluation Program led by theAmericanBotanical Coun-
cil of Austin, Texas, the ginsenosides Rb1, Rb2, Rc, Rd, Re, and
Rg1 account for >90% of the total ginsenoside content of the P.
ginseng root (Foster, 1996a,b; Chang et al., 2003). Whereas, gin-
senosides Rb1, Re, Rd, Rc, Rg1, and Rb3, the six major saponins,
make up more than 70% of total ginsenoside content in Ameri-
can ginseng (Wang et al., 2005). Ginsenosides are amphipathic in
nature. The hydroxyl (OH) group attached to the steroid back-
bone in ginsenosides allows interactions between the polar head
of the membrane phospholipids and the β-OH group of choles-
terol, while the hydrophobic steroid backbone can interact with
the hydrophobic side chains of fatty acids and cholesterol. These
physicochemical interactions are mostly determined by the num-
bers and sites of polar hydroxyl groups on each ginsenoside. Based
on such properties, ginsenosides with different numbers and sites
of hydroxyl groups exhibit diverse activities. Till date, more than
100 ginsenosides have been isolated from Panax species and most
of them exhibit four types of aglycone moieties (Liu and Xiao,
1992; Coates et al., 2005). Ginsenosides are classiﬁed into the
following types based on the steroidal skeleton and number of
hydroxyl groups/sugar moieties attached.
Protopanaxadiol
Protopanaxadiols (PPD; Figure 1) belong to the dammarane-type
ginsenosides, such as ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, and
Rb3, notoginsenoside R1, R2, Rs1, and Rs2, quinquenoside R1,
and malonylginsenoside Rb1, Rb2, Rc, and Rd (Sanada et al.,
1974; Kasai et al., 1983). More than 30 ginsenosides of the PPD
type belong to the Rb series (Dharmananda, 2002). The meta-
bolic pathway of the PPD-type ginsenosides has been extensively
investigated, resulting in identiﬁcation and characterizationof sev-
eral active metabolites, notably compound K (also referred to as
compound M1 or IH-901; Hasegawa et al., 1996).
Protopanaxatriol
Protopanaxatriols (PPT; Figure 2) are also dammarane-type gin-
senosides, including ginsenosidesRe,Rf,Rg1, andnotoginsenoside
R1. The main structural difference between PPT and PPD is the
presence of a hydroxyl group/sugar residue at C-6 in the PPT
moiety (Sanada et al., 1974; Kasai et al., 1983).
Oleanolic acid (or aglycone oleanolic acid)
This type, including ginsenosides Ro, has a pentacyclic triterpene
skeleton (Figure 2).
Ocotillol
This group has a ﬁve-membered epoxy ring at C-20 (Figure 2;
Nakamura et al., 2007). Majonoside R2 from the Vietnamese
ginseng is a prototype for this group (Konoshima et al., 1999).
POLYSACCHARIDES
Ginseng polysaccharides are water-soluble compounds contain-
ing various sugar moieties conjugated to uronic acid and include
panaxanes A to U. They are acidic polysaccharides and have
been shown to possess immunomodulating and anti-proliferative
effects. Recent studies have identiﬁed an acidic polysaccharide,
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FIGURE 1 | Chemical structures of protopanaxadiol-type ginsenosides.
referred to as “ginsan,” with immunostimulatory activity (Kim
et al., 1998; Shim et al., 2007).
POLYYNES
The polyynes are a group of organic compounds with alternat-
ing single and triple bonds. In ginseng, these include falcrinol
(panaxynol), falcarintriol (panaxytriol), acetic acid, or linolenic
acid (Lee and Zhao, 2009).
FLAVONOIDS AND VOLATILE OILS
Besides the compounds mentioned above, some ﬂavonoids and
volatile oils also have been isolated and identiﬁed from Panax
genus (Lee and Zhao, 2009).
STRUCTURE–ACTIVITY RELATIONSHIPS FOR GINSENOSIDE
ANTICANCER ACTIVITY
Ginseng saponins (except oleanic acid-type ginsenosides) possess
a four trans-ring rigid steroid skeleton, with a modiﬁed side chain
at C-20 and sugar residues attached to the -OH of the aglycone.
Structurally, most of the ginsenosides belong to PPD and PPT
groups (Qi et al., 2010). For the PPD group, the sugar residues
are attached to the β-OH at C-3 and another -OH at C-20 of the
aglycone, e.g., ginsenosides Rb1, Rb2, Rc, Rd, Rg3, and Rh2. For
the PPT group, sugar residues are attached to the α-OH at C-6
and another -OH at C-20 of the aglycone sapogenin, e.g., ginseno-
sides Re, Rg1, Rh1, and notoginsenoside R1 (Christensen, 2009).
Structure–activity relationships elucidate the association between
chemical structures and the pharmacological activities for a series
of compounds. As summarized in Table 1, the anticancer activities
of ginseng saponins are related to the following factors, including
the number of sugar molecules, number and position of hydroxyl
groups, and stereoselectivity (Qi et al., 2010).
NUMBER OF SUGAR MOLECULES
Anticancer activities increase with the decrease in the number of
sugar moieties in a ginsenoside molecule. Ginsenosides with four
or more sugar molecules, such as Rb1 and Rc, show no signif-
icant anti-proliferative effects (Yue et al., 2006; Li et al., 2009;
Wang et al., 2009a); while Rd with three sugar residues weakly
inhibits the growth of cancer cell (Yang et al., 2006; Li et al., 2009).
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FIGURE 2 | Chemical structures of protopanaxatriol-type, ocotillol-type and oleanic acid-type ginsenosides.
Ginsenosides Rg3 (two sugar residues), Rh2 (one sugar residue),
IH-901 (one sugar residue), PPT (no sugar residues), and PPD
(no sugar residues) inhibit different types of cancer cells and also
enhance the efﬁcacy of conventional chemotherapy agents when
given along with them (Hasegawa et al., 1995; Yue et al., 2006;
Wang et al., 2007a; Yu et al., 2007). Rh2, 25-OH-PPD, and PPD
show 5- to 15-fold relatively stronger anti-proliferative effects than
Rg3 (Wang et al., 2007b). Among these compounds, PPD with
no sugar residue shows the most potent anticancer activity. Qi
et al. (2010) claim that introducing acetyl groups at selected posi-
tions increases the anticancer activity of PPD. It has also been
suggested that neoglycorandomization might also increase anti-
cancer properties (Langenhan et al., 2005). One might also expect
to improve anticancer activity if heteroatoms like nitrogen and
sulfur atoms are integrated into the steroid core structure or on
the side chain.
Introduction of lipophilic groups in the side chains has been
shown to increase anti-proliferative activity (Qi et al., 2010). For
example, between the novel ginsenosides 25-OH-PPD and 25-
OCH3-PPD, both isolated from the fruits of P. notoginseng, the
latter shows a lower IC50 value in pancreatic cancer cell line
(Wang et al., 2009b,c). This type of modiﬁcation may also improve
the pharmacokinetic properties of the compound (Wang et al.,
2008b, 2009a,b). A related linear relationship has been observed
between Log Ps (also referred to as the lipophilicity) and Log
IC50 of ginsenosides (Li et al., 2009). The presence of sugar moi-
eties reduces the hydrophobic character of the compounds and
decreases the permeability of the cell membrane. As interaction
with the cell membrane decreases, so do the anticancer effects.
Thus we see that in general, anticancer activity is inversely corre-
lated to the number of sugar residues; a fact that may be attributed
to the cellular uptake capability of the ginsenosides. The cellular
uptake ratios of ginsenosides on cancer cells probably decrease
with the increase of sugar numbers, due to progressive decrease in
hydrophobicity (Ha et al., 2010).
SUGAR LINKAGE AT C-6
Differences in sugar linkage positions may also inﬂuence biologi-
cal responses. The C-6 substituent differentiates the PPD and PPT
groups of ginsenosides structurally. Ginsenoside Rh2 (PPD type)
and Rh1 (PPT type),which possess a glucose linkage at C-3 and C-
6, respectively, have similar chemical structures, but the anticancer
effect of Rh2 is stronger than that of Rh1. F1 (20-O-glc-PPT)
and Rh1 (6-O-glc-PPT) have the same number of sugar moieties
and the same molecular weight, with different glucose attachment
positions at C-20 and C-6, respectively. In a study on prostate can-
cer cell lines, F1 showed signiﬁcantly higher cell inhibition than
Rh1 (Li et al., 2009).
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Table 1 | Possible structure–activity relationships of ginsenosides against cancer.
Ginsenoside Nucleus No. of
sugars
Position of sugars/OH Anticancer activity Reference
C-3 C-6 C-12 C-20
Ra1 PPD 5 2 0 1-OH 3 None reported
Ra2 PPD 5 2 0 1-OH 3 None reported
Rb1 PPD 4 2 0 1-OH 2 Weakly anti-proliferative; anti-angiogenic Leung et al. (2007)
Rb2 PPD 4 2 0 1-OH 2 Weakly anti-proliferative; anti-angiogenic Mochizuki et al. (1995), Park and
Cho (2009)
Rb3 PPD 4 2 0 1-OH 2 No anti-anti-proliferative activity Xie et al. (2009)
Rc PPD 4 2 0 1-OH 2 No anti-proliferative activity Wang et al. (2009a), Li et al. (2009)
Rd PPD 4 2 0 1-OH 2 No signiﬁcant anti-proliferative activity Wang et al. (2009a), Li et al. (2009)
Compound K PPD 1 1 0 1-OH 0 Weakly inhibits cancer cell growth Wang et al. (2007a)
Re PPT 3 1-OH 2 1-OH 1 Not reported
Rf PPT 1 1-OH 1 1-OH 1-OH Not reported
Rg1 PPT 2 1-OH 1 1-OH 1 Anti-proliferative Wang et al. (2007a)
Rg2 PPT 3 1 2 1-OH 1-OH Anti-genotoxic Wang et al. (2007a)
Rg3 PPD 2 2 0 1-OH 1-OH Anti-proliferative, apoptotic Wang et al. (2007a)
Rh1 PPT 1 1-OH 1 1-OH 1-OH Strongly anti-proliferative Jung et al. (2010a,b)
Rh2 PPD 1 1 0 1-OH 1-OH Strongly apoptotic Cheng et al. (2005)
25-OH-PPT PPT 0 1-OH 1-OH 1-OH 1-OH Weakly anti-proliferative Wang et al. (2007b), Wang et al.
(2008a)
25-OH-PPD PPD 0 1-OH 0 1-OH 1-OH Apoptosis; anti-proliferation Wang et al. (2007b), Wang et al.
(2008a), Wang et al. (2009b)
25-OCH3-PPD PPD 0 1-OH 0 1-OH 1-OH Highly anti-proliferative and anti-apoptotic Wang et al. (2008b), Wang et al.
(2009a), Wang et al. (2009b)
PPD, protopanaxadiol-type; PPT, protopanaxatriol-type.
With a sugar substitute at C-6, the anticancer activity of gin-
senosides is decreased compared to activity with linkages at C-3 or
C-20. Molecular modeling and docking experiments conﬁrm that
the presence of a sugar moiety at C-6 increases the steric hindrance
for these molecules to bind to their target proteins by blocking
entrance into the extracellular binding pocket, and thus signif-
icantly reducing the anticancer activities of ginsenosides (Chen
et al., 2009).
HYDROXYL GROUPS
It is known that polar substances interact with phospholipid
head groups in the hydrophilic domain of the cell membrane.
Ginsenosides interact with the β-OH of the cholesterol in the
cell membrane and intercalate themselves into the plasma mem-
brane. This leads to changes in membrane ﬂuidity, and thus
affects membrane function, eliciting a cellular response. This abil-
ity to insert and orient with the membrane is inﬂuenced by the
number and site of polar hydroxyl groups. Differences in the
number and position of hydroxyl groups inﬂuence pharmaco-
logical activity. Elimination of the double bond at C-24/25 and
addition of hydroxyl or methoxyl at C-25 increases the anti-
cancer potential of ginsenosides. The anticancer activities of
25-OCH3-PPD, 25-OH-PPD, 25-OH-PPT, PPD, Rh2, and Rg3
have been systematically compared. 25-OCH3-PPD and 25-OH-
PPD show the most potent anti-proliferative, pro-apoptotic, cell
cycle regulatory and inhibitory effects of tumor growth in vivo
and appear to be promising candidates for further develop-
ment as novel anticancer agents (Wang et al., 2007b, 2008a,b,
2009a,b).
Dehydration at C-20 increases the bioactivity of ginsenosides
(Kang et al., 2006). Rg5 differs from Rg3 only by the presence of
a hydroxyl group at C-20 in Rg3 and is approximately four times
more effective than Rg3 at inhibiting cell proliferation (Lee et al.,
1997; Shin et al., 2006). Rh3, however, is a dehydration product at
C-20 of Rh2; both Rh2 and Rh3 induce differentiation of promye-
locytic leukemia HL-60 cells, but the potency of Rh2 seems to be
higher (Kim et al., 1998).
STEREOSELECTIVITY OF 20(S ) AND 20(R )
20(S) and 20(R) forms of ginsenosides are stereoisomers of each
other that depend on the orientation of the C-20 hydroxyl in gin-
senosides. 20(S)-OH is spatially close to the C-12 hydroxyl of
ginsenosides while 20(R)-OH is far. This difference in the stereo-
chemistry produces different pharmacological effects. 20(S)-Rg3
scavenges hydroxyl radicals better than 20(R)-Rg3 (Lee et al.,
2008). 20(S)-Rg3 is better aligned with the hydroxyl acceptor
group in the ion channels than 20(R)-Rg3, making 20(S)-Rg3
an efﬁcient regulator of voltage-dependent ion channels. Voltage-
sensitive ion channels have been shown to play a signiﬁcant role
in the progression of cancer (Jeong et al., 2004; Fiske et al., 2006).
In general, the 20(S) compounds have been shown to possess bet-
ter anti-proliferative effects than their 20(R) counterparts whereas
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20(R) compounds such as 20(R)-Rg3 have been shown to inhibit
cancer cell invasion and metastasis.
Although a limited effect against cancer is observed, 20(R)-
Rh2 inhibits osteoclast formation better than 20(S)-Rh2. It is
possible that the anti-tumor properties of 20(R) ginsenosides
are in part mediated through their angiosuppressive activity.
These observations imply that the stereostructure of the C-20
hydroxyl may inﬂuence the biological and pharmacological effects
of ginsenosides (Yue et al., 2006; Qi et al., 2010).
METABOLISM
When taken orally, PPD-type ginsenosides are mostly metabolized
by anaerobic intestinal bacteria such asBacteroides,Fusobacterium,
Eubacterium, and Provetella to a PPD monoglucoside, compound
K, via a step-wise cleavage of the sugar moieties (Lee et al., 2009a).
In humans, compound K may be detected in the plasma from 7 h
after the intake of PPD-type ginsenosides and in urine from 12 h
after the intake. These ﬁndings suggest that compound K is the
ﬁnal metabolite of PPD-type ginsenosides (Lee et al., 2009a). Also,
compound K exhibits moderate inhibition of the CYP2C9 activity,
while PPD and PPT exhibit potent competitive inhibition against
CYP3A4 activity (Hasegawa et al., 1996; Tawab et al., 2003).
MOLECULAR MECHANISMS OF ANTICANCER ACTIVITIES OF
GINSENG AND GINSENG PRODUCTS
The initiation of tumorigenesis involves DNA alteration, which
may be heritable in progeny cells. These alterations include muta-
tions, oncogene activation rearrangements, ampliﬁcations, and
methylation. The commencement of this transformation process
is irreversible and is modiﬁed by agents that may act as promoters.
Initiation and promotion give rise to an abnormal expression of
cellular genes whose interaction hormones with cellular receptors
trigger a cascade of intracellular biochemical signals resulting in
the activation and repression of various subsets of genes. Hence,
determining the molecular mechanisms in the development and
progression of the neoplastic process is essential for understand-
ing the activity of any compound.Although anticancer activities of
ginsengproducts have beenwidely reported, the exactmechanisms
of action are not fully understood. Based on the existing reports,
we summarize the possible molecular mechanisms by which gin-
senosides exert anticancer effects in the following text (Table 2;
Figure 3).
MODULATION OF TUMOR CELL GROWTH, CELL CYCLE, AND CELL DEATH
(FIGURES 4 AND 5)
Effects on DNA damage
An aqueous extract of ginseng root has been shown to exert a
radioprotective effect against γ-ray induced DNA double stranded
breaks and repair in cultured mouse lymphocytes; and reduce
the relative strand scission factor (RSSF) by a factor of 2 (Kim
et al., 1996). Several studies have shown that ginseng root extracts
exhibit both lipid-soluble and water-soluble antioxidant activity
(Lee et al., 2005b). This antioxidant action is mediated through
free radical scavenging and through upregulation of antioxi-
dant enzymes, thus attenuating DNA degradation. Both Cu/Zn-
superoxide dismutase (Cu/Zn-SOD or SOD1) and catalase (CAT)
are key enzymes involved in the metabolism of oxygen free radi-
cals, and ginsenosides have been associated with the upregulation
of these two enzymes at the level of gene expression and transcrip-
tion (Rhee et al., 1991; Zhang et al., 1996; Kitts et al., 2000; Kim
et al., 2002; Keum et al., 2003).
Effect on proliferation and differentiation
Studies show that, of all naturally occurring ginsenosides in the
American ginseng plant Rg3, has the most potent effect on inhi-
bition of cell proliferation. In fact, steam treatment increasing the
concentration of ginsenoside Rg3 augments the anti-proliferative
activities of American ginseng (Wang et al., 2007a). In the human
prostate carcinomaLNCaP cell line, ginsenoside Rg3 displays good
growth inhibitory activity. The expression of biomarker genes,
including prostate speciﬁc antigen (PSA), androgen receptor (AR)
and 5alpha-reductase (5alphaR), and that of the proliferating cell
nuclear antigen (PCNA) are suppressed (Liu et al., 2000). Rh2
obtained from Asian ginseng also shows anti-proliferation, differ-
entiation, and chemopreventive effects in various cancer cell types
(Oh et al., 1999).
Studies show that p21 is an important target in mediating the
anti-proliferative activities of ginseng. American ginseng extract
(AGE) inhibits breast cancer cell proliferation by induction of this
important cyclin inhibitor protein (King and Murphy, 2006). Rh2
has also been shown to inhibit cell growth in a concentration-
dependent reversible manner, inducing a G1 arrest in cell cycle
progressionbyupregulating the expressionof p21 (Ohet al., 1999).
Ginseng is found to have the ability to induce transformation of
neoplastic cells into normal cells (Lee et al., 2009b). Rh2 present in
red ginseng inhibits the growth and colony forming ability of Mor-
ris hepatoma cells in soft agar suspension culture, and stimulates
serum protein synthesis of these cells, thus transforming the neo-
plastic cells functionally and morphologically to those resembling
original normal liver cells, a process known as “redifferentiation”
(Odashima et al., 1989). Red ginseng (also known as Korean
red ginseng) is a processed form of unpeeled ginseng that has
been heated, either through steaming or sun-drying and contains
predominantly the PPD ginsenosides (Lui and Staba, 1980).
Similarly, Rh1 and Rh2 cause differentiation of F9 teratocar-
cinoma stem cells via binding to a steroid receptor (Lee et al.,
1993). Furthermore, Rh2 signiﬁcantly induces B16 cell differenti-
ation and increases melanin synthesis in B16 cells (Xia and Han,
1996). Cytotoxic effects of the PPD or PPT type of ginsenosides
are inversely proportional both to the number of sugars attached
to the aglycones and to the number of hydroxyl groups of the agly-
cones. Surprisingly, the type of side chain and the conﬁguration
of the hydroxyl group at C-3 in aglycones have not been found to
play a signiﬁcant role in determining cytotoxicity (Atopkina et al.,
1999). Rg3 and Rh2 inhibit the proliferation of prostate cancer cell
lines LNCaP and PC3, which may be associated with modulation
of MAP kinases (MAPK; Kim et al., 2004). In addition, 20(S)-PPD
and Rh2 reduce cell proliferation and increase sub-G1 cells in two
cultured intestinal cell lines, Int-407 and Caco-2 (Popovich and
Kitts, 2004).
Cell cycle regulation and regulation of p53/p21/MDM2 pathway
The cell cycle is a set of events, resulting in cell growth and divi-
sion into two daughter cells. The stages are G1–S–G2–M. The
G1–S transition in the cell cycle is controlled primarily via cyclin
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Table 2 | Summary of the anticancer activities of major ginsenoside.
Ginsenoside Source Nucleus Anticancer activity Molecular mechanism References
Ra1 P. quinquefolium PPD None reported None reported
Ra2 P. quinquefolium PPD None reported None reported
Ra3 P. quinquefolium PPD None reported None reported
Rb1 P. quinquefolium PPD Weakly
anti-proliferative;
anti-angiogenic
Inhibits capillary genesis; inhibits PEDF
through estrogen receptor-β; inhibits
TNF-α release; protects against
oxidative stress.
Hwang and Hye (2010)
Rb2 P. quinquefolium PPD Weakly
anti-proliferative;
anti-angiogenic
Inhibits MMP-2; inhibits TNF-α release Xu et al. (2008)
Rb3 P. quinquefolium PPD No anti-proliferative
activity
Inhibits TNF-α release Xie et al. (2009)
Rc P. quinquefolium PPD No signiﬁcant
anti-proliferative activity
No particular mechanism reported Wang et al. (2009a), Li et al.
(2009)
Rd P. quinquefolium PPD Weakly inhibits cancer
cell growth
No particular mechanism reported Wang et al. (2009a), Li et al.
(2009)
Re P. quinquefolium PPT Not reported Not reported
Rf P. ginseng PPT Not reported Not reported
Rg1 P. quinquefolium PPT Anti-proliferative Inhibits oncogenes c-myc, c-fos;
downregulates nucleophosmin
Li et al. (2008)
Rg2 P. ginseng PPT Anti-genotoxic Increases levels of p53 and p21 Wang et al. (2007a)
Rg3 P. quinquefolium PPD Anti-proliferative;
apoptotic
Regulates mitochondrial cytochrome C,
PARP, and C9; inhibits MMp-2 and 9;
inhibits adhesion of metastatic cells to
basement membrane.
Yue et al. (2006), Xu et al.
(2008)
Rg5 P. quinquefolium PPD Strongly
anti-proliferative
No particular mechanism reported Lee et al. (1997), Shin et al.
(2006)
Rh1 P. quinquefolium PPT Causes differentiation
of teratocarcinoma
cells; strongly apoptotic
Binds to steroid receptor; Inhibits
TNF-α; Inhibited phosphorylation of
JAK1, STAT1, STAT3, and ERK.
Jung et al. (2010a,b), Lee
et al. (1993)
Rh2 P. quinquefolium PPD Induces differentiation
of promyelocytic
leukemia HL-60 cells;
Inhibits osteoclast
formation
Modulation of MAP kinases; increases
sub-G1 cells; activates caspase-3 via
Bcl-2 insensitive pathway; induce Fas
receptor aggregation in a
FasL-independent manner; regulates
protein kinase A (PKA) pathway and
the LPS/IFN-g-induced DNA-binding
activity of AP-1; induced apoptosis via
death receptor TRAIL-R1/DR4; inhibit
the transport function of P-glycoprotein
Cheng et al. (2005), Choi
and Choi (2009), Park et al.
(1997), Kim et al. (2004), Li
et al. (2011), Li et al. (2008),
Odashima et al. (1989), Oh
et al. (1999), Park et al.
(1997), Popovich and Kitts
(2004), Yi et al. (2009)
Rp1 Semi-synthetic PPD Inhibits IL-1 production;
downregulation of the IGF-1R/Akt
Kang et al. (2011), Kim et al.
(2009)
Notoginsenoside R1 P. notoginseng PPT Anti-proliferative Inhibits TNF-α Liu et al. (2010)
Notoginsenoside R2 P. notoginseng PPT No particular mechanism reported
Majonoside R2 P. vietnamensis OT Anti-proliferative No particular mechanism reported
Ginsenoside Ro P. ginseng OA None reported No particular mechanism reported
Chikusetsusaponin IV P. japonicus OA None reported No particular mechanism reported
Compound K metabolite PPD Apoptosis;
Anti-proliferation
Inhibits COX-2 and production of
PGE2; downregulates Akt
phosphorylation; inhibits MMP-9
Jeong et al. (2010), Jung et al.
(2006), Jung et al. (2010a,b),
Kang et al. (2005), Kim et al.
(2010a), Lee et al. (2010),
Wong et al. (2010)
(Continued)
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Table 2 | Continued
Ginsenoside Source Nucleus Anticancer activity Molecular mechanism References
25-OH-PPT P. notoginseng PPT Weakly anti-proliferative No particular mechanism reported Wang et al. (2007b), Wang
et al. (2008a)
25-OH-PPD P. notoginseng PPD Apoptosis;
anti-proliferation
Downregulation of MDM2; activation
of caspases; increase in p21
Wang et al. (2007b), Wang
et al. (2008a), Wang et al.
(2009b)
25-OCH3-PPD P. notoginseng PPD Apoptosis;
anti-proliferation
Downregulation of MDM2, activation
of caspases, increase in p21
Wang et al. (2008b), Wang
et al. (2009a), Wang et al.
(2009b)
PPD, protopanaxadiol-type; PPT, protopanaxatriol-type; OT, ocotillo-type; OA, oleanic acid-type.
FIGURE 3 | Possible cellular and molecular mechanisms of
ginsenosides aginst cancer. CDKs, cyclin-dependent kinases; MDM2,
murine double minute-2; VEGF, vascular endothelial growth factor; bFGF,
basic ﬁbroblast growth factor; PDGF, platelet derived growth factor, MMP,
matrix metalloproteinase; IAP, inhibitory apoptotic protein; TNF, tumor
necrosis factor; NF-κB, nuclear factor κB; PI3K, Phosphatidylinositol
3-kinase; HIF-1, hypoxia-inducible factor-1; ERK, extracellular
signal-regulated kinase; NRF2, nuclear factor (erythroid-derived 2)-like;
AMPK, 5′ AMP-activated protein kinase; EGF, epithelial growth factor; ↑,
upregulation; ↓, downregulation.
pathways, including cyclin D1 and cyclin cdks 2, 4, and 6. These
proteins are, in turn, regulated by p21 andp27.At the very center of
this cell cycle regulation is the tumor suppressor and transcription
factor p53. The tumor suppressor p53 plays an important role
in regulation of cell cycle and apoptosis. The MDM2 oncopro-
tein is an E3 ubiquitin ligase negatively regulates p53 function by
conjugating ubiquitin to p53; thus altering its cellular localization
and tagging it for proteasomal degradation.
Panaxydol, a polyacetylene compound obtained from P gin-
seng, induces cell cycle arrest at the G1 to S transition in
HepG2 hepatoma cancer cells with concomitant increase in the
protein levels of p21, pRb, and hypophosphorylated pRb in a
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FIGURE 4 | Cell signaling pathways involved in cell cycle arrest targeted by selected ginsenosides. Rb, retinoblastoma protein.
FIGURE 5 | Cell signaling pathways involved in apoptotic response targeted by selected ginsenosides. KRG, Korean red ginseng; AG: American ginseng.
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dose-dependent manner (Guo et al., 2009). Rs3, a panaxadiol
type ginsenoside isolated from the Korean red ginseng, upreg-
ulates p53 leading to induction of p21 which in turn initiates
growth arrest and apoptosis. Studies show that ginsenosides selec-
tively increase p53 expression at G2 phase of carcinoma cells and
release cytochrome c from mitochondria, which is an essential
requirement for apoptosis. An aqueous extract of Asian ginseng
has been shown to induce MAPK and p53 signaling in LLC-1
cells, which suppresses cyclin B-cdc2 complex and in turn induces
G2–M arrest and apoptosis. Compound K is known to induce the
expression of p21, independently of p53 in U937 human mono-
cytic leukemia cells (Kang et al., 2005; Jung et al., 2006; Wong
et al., 2010).Wang et al. demonstrate that 25-OH-PPD inhibits cell
growth and proliferation, induces apoptosis, and leads to arrest in
the G1 phase of the cell cycle in prostate cancer. Further, in both
PC3 and LNCaP prostate cancer cell lines, 25-OH-PPD reduces
expression of MDM2, E2F1, Bcl-2, cdk2/4/6, and cyclin D1, which
correlates with cell cycle arrest in G1 phase and anti-proliferative
activity (Wang et al., 2007b).
Induction of cell death
There are two major pathways of cell death: apoptosis (death by
suicide) and necrosis (death by injury). Apoptosis, also known as
programmed cell death, involves a series of biochemical events,
leading to characteristic cell morphology and death. It is typi-
cally accompanied by activation of speciﬁc proteases known as
caspases (Nicholson and Thornberry, 1997). Necrosis is caused by
external factors, such as infection, toxins, or trauma. Additional
cell death mechanisms, such as autophagy (degradation of a cell’s
own components through the lysosomal action), entosis (inter-
nalization of a cell detached from the basement membrane into
another cell; Overholtzer et al., 2007), paraptosis (non-apoptotic
cell deathmediated byMAPKs; Sperandio et al., 2004), and anoikis
have been deﬁned more recently.
Caspase activation. Caspases, or cysteine–aspartic acid pro-
teases, are a family of cysteine proteases that play essential roles
in apoptosis, necrosis, and inﬂammation. Numerous reports sug-
gest the involvement of caspases in ginsenoside-induced apoptosis.
Ginsenosides cause DNA damage, endoplasmic reticulum (ER)
stress, and mitochondrial-dependent-induced apoptosis through
the activation of caspase-3 (Cheng et al., 2005). Compound K
has been shown to cause loss of the mitochondrial membrane
potential followed by cytochrome c release from the mitochon-
dria, resulting in the activation of caspase-9, -3, and concomitant
polyADP-ribosyl polymerase (PARP) cleavage,which are the indi-
cators of caspase-dependent apoptosis (Lee et al., 2010). Caspase-8
plays a key role in compound K-stimulated apoptosis via the
activation of caspase-3 directly or indirectly through Bid cleav-
age, cytochrome c release, and caspase-9 activation. Rg3 has been
shown to facilitate the release of mitochondrial cytochrome c,
PARP, caspase-9, and caspase-3 (Lee et al., 2010).
Aqueous extracts of American ginseng activate BAX and
increase the levels of cleaved caspase-3 in p21-deﬁcient cells caus-
ing cell death (King and Murphy, 2010). Korean red ginseng causes
an increase in apoptosis, by downregulation of anti-apoptotic
Bcl-2, Bcl-XL, and IAPs family members, and the activation of
caspase-3 (Cheng et al., 2005). Rh2 activates caspase-3 via Bcl-2
insensitive pathway in the human hepatoma cell line SK-HEP1
(Park et al., 2010a). In structure and apoptosis relationship, the
presence of sugars in PPD and PPT aglycone structures has been
found to reduce the potency to induce apoptosis in the human
leukemia (THP-1) cell line (Popovich and Kitts, 2002).
Induction of death receptors. Death receptors are cell surface
receptors that transmit apoptotic signals initiated by speciﬁc lig-
ands such as Fas ligand, tumor necrosis factor-α (TNF-α), and
TRAIL (TNF related apoptosis-inducing ligand). These recep-
tors play a crucial role in apoptosis and can activate a caspases-8
dependent cascade within seconds of ligand binding. Induction
of apoptosis via this mechanism is therefore very rapid. Stud-
ies show that the ginsenosides such as Rh2 induce apoptosis via
death receptor TRAIL-R1/DR4 in the human lung adenocarci-
noma cell line A549. However, expression of Bcl-2 protein in A549
cells does not block Rh2 mediated apoptosis, suggesting that the
DR4 pathway acts independently of the Bcl-2 family (Cheng et al.,
2005; Choi and Choi, 2009). Intestinal bacterial metabolites of
ginseng saponin such as compound K induce apoptosis in human
hepatoblastoma cells by late activation of caspase-8 by Bid and
DR5 (Lee et al., 2010). Contrastingly, studies with Korean RGE in
U937 leukemia cell line show no change in levels of DR4, DR5,
and TRAIL but the extract induces concomitant degradation of
poly (ADP-ribose) polymerase, β-catenin and PLC-γ1 substrate
proteins of caspase-3 (Park et al., 2009).
FAS receptor aggregation. Fas receptor is the ligand for Fas-
activated apoptosis. Binding of the ligand promotes receptor clus-
tering, DISC formation, and the activation of the caspase cascade.
The ginsenoside Rh2 is shown to induce Fas receptor aggregation
in a FasL-independent manner (Yi et al., 2009). Apoptosis in the
HeLa cell line NCE induced by Rh2 upregulates the Fas receptor
protein in a dose-dependent manner (Park et al., 1997). Ginseno-
sides are able to inhibit the proliferation of cancer cells and induce
apoptosis by downregulating the expression of c-myc and Bcl-2
and upregulating the expression of Fas and p53. They also induce
the cell cycle arrest and apoptosis in gastric/colon cancer cells and
stimulate the activity of caspase-8, initiating Fas signaling pathway
of apoptosis (Yi et al., 2009).
Autophagy. Autophagy is a type of programmed cell death occur-
ring in response to cellular stress and starvation. Unlike apoptosis,
in autophagy there is no cell enlargement, bleb formation, vacuole
development, and enlarged/swollen nuclei (Elliott and Reiners,
2008). The ginsenoside Rk1 obtained from heat processed ginseng
induces both G1 phase arrest and autophagy, but not apoptosis,
at an earlier stage of treatment. Rk1-induced autophagy is docu-
mented by the conversion of microtubule associated protein light
chain 3 (LC3)-I to LC3-II, an autophagosome marker, and mon-
odansylcadaverine (MDC) incorporation into autolysosomes (Ko
et al., 2009).
MODULATION OF PATHWAYS INVOLVING GROWTH SIGNALS
Growth factors play a critical role in the proliferation of tumor
cells. Molecules like EGF, HER2, FGF, vascular endothelial growth
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factor (VEGF),PDGF,and insulin growth factor (IGF)-1 have been
associated with cell proliferation. The suppression of these growth
factors or their receptors results in inhibition of tumor growth.
For example, the inhibition of EGFR expression and decreased
ERK1/2 activity attenuates cell survival and enhances induction of
apoptosis in lung and pancreatic adenocarcinoma cells.
Inhibition of growth factors and their receptors
Several studies have shown that ginsenoside are capable of block-
ingVEGF. Rg3 is reported to downregulate the expressions of KDR
(VEGF receptor-2) and VEGF protein and their mRNA in human
lung squamous cancer SK-MES-1 cells (Wang et al., 2009d). It
is reported that ginsenoside Rg3 and cyclophosphamide (CTX)
exhibit a synergistic effect on the inhibition of growth and angio-
genesis in mice transplanted with ovarian cancer cells (SKOV-3;
Xu et al., 2007). The treated mice show decreased PCNA labeling
index and theVEGFexpression is also signiﬁcantly lower.Ginseno-
sides have also been shown to completely block EGF-inducedDNA
synthesis and cell growth in primary cultured rabbit renal prox-
imal tubular cells (PTCs; Han et al., 2002). In contrast, the PPT
and PPD fractions only cause partial blockade. In addition, the
EGF-induced increase of c-fos and c-jun gene expression is com-
pletely blocked by total ginsenosides and partially by PPT and PPD
saponins (Han et al., 2002). Compound K reduces the secretion of
VEGF and increases the secretion of pigment epithelium-derived
factor (PEDF) in HUVECs. In addition, Compound K effectively
disrupts bFGF-induced neovascularization in the Matrigel plugs
excised from mice in vivo (Jeong et al., 2010). A recent study
(Dougherty et al., 2011) suggests that compound K inhibits the
activation of EGFR signals, including pEGFR, pErbB2, pERK, and
pAKT in an inﬂammation associated colon cancer model based
on a high fat western diet.
Ephrin pathway
Ephrin receptors belong to the tyrosine kinase family of trans-
membrane proteins, capable of inﬂuencing cell–cell interaction
and cell migration. When Ephrins bind to Eph receptors, the bidi-
rectional signaling of the Eph/ephrin axis is activated; this results
in tumorigenesis and is associated with angiogenesis and metas-
tasis in many types of human cancer. Previously, the inhibition of
Eph/ephrin signaling as a novel strategy for cancer treatment has
been investigated. Using ChIP and microarray techniques, Luo et
al. show that ginsenosides Rg3 and S2H may exert effective anti-
cancer activity through the Ephrin receptor pathway in human
colorectal cancer cell line HCT116. The microarray analysis sug-
gests that the activity of Rg3 is linked to upregulation of AKAPA8L
(anchor protein) and downregulation of PITPNA (phosphatidyli-
nositol transfer protein α) genes (Park et al., 2005; Luo et al., 2008).
INHIBITION OF ANGIOGENESIS
Angiogenesis is the process by which new blood vessels are formed
from pre-existing structures. It is a crucial step in tumor growth
and metastasis by supplying oxygen and nutrients. Ginseng deriv-
atives have been shown to inhibit tumor growth by inﬂuenc-
ing neovascularization and the angiogenesis-related properties of
endothelial cells (ECs; Leung et al., 2007). Ginsenoside Rb1 has
been shown to inhibit capillary morphogenesis of ECs by regulat-
ing expression of PEDF through the estrogen receptor α (Leung
et al., 2007). 20(R)-Rg3 inhibits proliferation, formation of cap-
illary tube, and chemoinvasion of ECs induced by VEGF (Yue
et al., 2006). 20(R)-Rg3 also reduces microvascular sprouting in
vitro and inhibits neovascularization induced by basic ﬁbroblast
growth factor in vivo (Yue et al., 2006). The angiosuppressive effect
of 20(R)-Rg3maybe related to the differential regulation of matrix
metalloproteinases (MMP-2 and MMP-9) activities (Yue et al.,
2006).
ANTI-METASTATIC EFFECTS
Metastases are multiple, widespread tumor colonies established
by malignant cells that detach themselves from the original tumor
and travel through the body often to distant sites. Some of these
invading cells penetrate into a body cavity or the blood, lymph or
spinal ﬂuid and then are released forming tumors locally at the
site of penetration. Enzymes capable of proteolytic degradation of
extracellular matrix and basement membranes have been impli-
cated in tumor progression and metastasis, especially the protease
matrix metalloproteinase 9 (MMP-9). Matrix metalloproteinases,
a family of zinc-dependent proteases, participate in several steps
in tumor progression, including invasion, metastasis, and angio-
genesis. Many studies implicate that the aberrant expression of
MMP-9 plays an important role in tumor metastasis (Deryugina
and Quigley, 2006).
20(R)- and 20(S)-Rg3 possess an ability to inhibit the lung
metastasis of tumor cells such as B16-BL-6 melanoma and colon
26M3.1 by inhibition of the adhesion and invasion of tumor cells,
and also by anti-angiogenesis activity (Mochizuki et al., 1995).
Glucocorticoid receptor-induced downregulation of MMP-9 by
panaxadiol (PD) and panaxatriol (PT) appear to be associated
with the reduced invasive capacity of HT1080, a highly metastatic
human ﬁbrosarcoma cell line (Park et al., 1999).
Mochizuki et al. report that multiple administration of gin-
senoside Rb2 after the intravenous inoculation of B16-BL6
melanoma cells results in a signiﬁcant inhibition of tumor associ-
ated angiogenesis leading to suppression of lung metastases. In
addition, the authors also show that Rg3 signiﬁcantly inhibits
the adhesion and invasion of B16-BL6 cells into reconstituted
basementmembranes (Matrigel;Mochizuki et al., 1995). Ginseno-
side Rb2 has been reported to inhibit invasion to the basement
membrane via MMP-2 suppression in some endometrial can-
cers such as HHUA and HEC-1-A cells, and can potentially be
used as a medication for inhibition of secondary spreading of
uterine endometrial cancers (Fujimoto et al., 2001). It is shown
that ginsenoside Rg3 inhibits experimental pulmonary metastasis
by highly metastatic mouse melanoma B16FE7 cells, by inhibi-
tion of the 1-oleoyl-lysophosphatidic acid (LPA)-triggered rise of
intracellular Ca2+ (Shinkai et al., 1996). In addition, the invasive
ability and MMP-9 expression of SKOV-3 cells decreases signif-
icantly after treatment with ginsenoside Rg3 (Xu et al., 2008).
Compound K is effective in suppressing the expression of MMP-9
and thus inhibiting migration and invasion in metastatic murine
colon adenocarcinoma cells (Choo et al., 2008). In another study,
the aforementioned ginsenoside has also been shown to inhibit
the secretion and protein expression of MMP-9 in astroglioma
cells. The inhibitory effect of compound K on MMP-9 expression
correlates with decreased MMP-9 mRNA levels and suppression
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of MMP-9 promoter activity. The compound K-mediated inhi-
bition of MMP-9 gene expression occurs via activator protein-1
(AP-1) because its DNA-binding and transcriptional activities are
suppressed by the drug (Jung et al., 2006).
Recently, a study (Yoon et al., 2012) has shown that treatment
with the Rd inhibits migration and invasion of the liver cancer cell
line HepG2. This is accomplished by reducing the expression of
MMP-1, MMP-2, and MMP-7, by blocking MAPK signaling, by
inhibition of AP-1 activation, and by inducing focal adhesion for-
mation and decreasing vinculin localization and expression. This
leads to a signiﬁcant anti-metastatic effect. Earlier studies have
reported that Rd has negligible anti-proliferative activities (Wang
et al., 2007a).
MODULATION OF KINASES (FIGURE 6)
Inhibition of PI3K-Akt activation
Akt (protein kinase B), a serine/threonine kinase, is a critical
enzyme in signal transduction pathways involved in cell prolif-
eration, apoptosis, and angiogenesis. Studies show that several
ginsenosides such as compound K and PPDs inhibit the phos-
phorylation of Akt, mTOR, and their downstream substrates in
a concentration- and time-dependent manner in human umbil-
ical vein cells, and this inhibitory effect is seen downstream of
phosphatidylinositol 3-kinase (PI3K). In ﬁbroblast growth factor
treated HUVEC cells, compound K downregulates the phospho-
rylation of Akt (Jeong et al., 2010). Additionally, in MCF-7 cells,
20(S)-PPD has been shown to synergistically enhance the cyto-
toxicity of tamoxifen by downregulating Akt, independently of
estrogen receptor (Yu et al., 2007).
Activation of c-jun kinase
Studies show that activation of the JNK/c-Jun/AP-1 signal pathway
induces the p21 activation, resulting in growth arrest. Compound
K causes G1 phase arrest via the induction of p21 and activation
of the JNK/AP-1 pathway. The apoptotic effect of compound K
is exerted via the activation of c-Jun NH2-terminal kinase (JNK)
and p38 MAPK (Kang et al., 2005; Jeong et al., 2010). Another
study shows that panaxydol induces apoptosis through an increase
in intracellular Ca2+ concentration, activation of JNK and p38
MAPK, and generation of reactive oxygen species (ROS) initially
by NADPH oxidase and then by mitochondria. Apoptosis seen is
caspase-dependent and occurs through a mitochondrial pathway
utilizing generated ROS (Kim et al., 2011).
Modulation of AMPK pathways
AMP-activated protein kinase (AMPK) is a sensor of cellular
energy states and is involved in apoptosis of cancer cells. Many
cancers are characterized by increased expression and/or activity
of enzymes (e.g., FAS and mTOR) that are inhibited by AMPK.
Compound K is shown to exert cytotoxicity in MCF-7 human
breast cancer cells through modulation of AMPK, followed by
a decrease in cyclooxygenase-2 (COX-2) expression (Kim et al.,
2010a). Compound K inhibits cell growth, induces apoptosis via
generation of ROS, as well as decreasing COX-2 expression and
prostaglandin E2 (PGE2) levels. These effects of compound K are
induced via an AMPK-dependent pathway and are nulliﬁed by a
speciﬁc AMPK inhibitor (Kim et al., 2010a).
ANTI-INFLAMMATORY PATHWAYS
Chronic inﬂammation is associated with increased cancer risk.
The microenvironment provided by inﬂammatory cells is a crucial
contributor in the neoplastic process, fostering proliferation,
survival, and migration (Aggarwal and Shishodia, 2006). The
inﬂammatory cells and regulators may facilitate angiogenesis and
promote the growth, invasion, and metastasis of tumor cells.
Compound K suppresses the TNF-α-induced activation of
nuclear factor kappa-B (NF-κB), expression of MMP-9,migration
and invasion of cancerous cells, thus indicating that ginsenosides
have the potential to suppress inﬂammation related metastasis
(Choo et al., 2008). American ginseng has been shown to inhibit
inducedCOX-2 andNF-κBactivation inMDA-MB-231 andMCF-
7 cell line (Peralta et al., 2009). Rg3 suppresses activation of NF-κB
inhibiting cancer cell growth in colon cancer cell lines SW620 and
HCT116 in a dose-dependent manner (Kim et al., 2010b). Block-
age of ROS by NAC/catalase inhibits activation of NF-κB signaling
increasing Rh2 induced cell death (Li et al., 2011).
The ginsenoside G-Rp1 dose-dependently inhibits interleukin-
1 (IL-1) production (at both mRNA and protein levels) from
LPS-treated RAW264.7 cells without altering cell viability. This
compound also downregulates IκBα phosphorylation and NF-κB
activation, but does not affect the upstream signaling enzymes
such as MAPK and p85, a regulatory subunit of PI3K (Kim et al.,
2009). PPD-type ginsenosides (G-Rb1 and G-Rb2) exhibit signif-
icant inhibition of TNF-α release with IC50 values of 48.0 and
27.9 mM, respectively (Park and Cho, 2009). Strong apoptosis-
inducing saponins, Rh1 and Rh2, the main intestinal metabolites
of Rg3 have been shown to be inhibitors of proinﬂammatory TNF-
α and IL-1b in LPS/IFN-g-activated BV-2 cells, while increasing
the expressionof the anti-inﬂammatory cytokine IL-10 (Jung et al.,
2010a,b). The prime targets of G-Rh2 are both the protein kinaseA
(PKA) pathway and the LPS/IFN-g-induced DNA-binding activity
of AP-1, but not the cAMP responsive element binding protein or
NF-κB. Both PPD and PPT type ginsenosides inhibit LPS-induced
TNFα by blocking the phosphorylation of ERK 1/2, JNK, and c-
Jun, as well as blocking NF-κB activation (Wu et al., 2007). RGE
from steamed and dried P. ginseng is seen to inhibit Helicobacter
pylori-induced MAPK signaling by repressing either nuclear fac-
tor NF-κB–DNA-binding activity or release of IL-8 and COX-2
in gastric epithelial cells (Park et al., 2007). RGE also inactivates
c-Jun phosphorylation and represses redox-sensitive transcrip-
tional activation, leading to reduced expression of IL-8 and 5-LOX
mRNA in gastric mucosal cells (Park et al., 2007).
Rh1 signiﬁcantly suppresses IFN-γ-induced iNOS promoter
activity by inhibiting DNA-binding of several transcription fac-
tors, such asNF-κB, IRF-1, and STAT1 (Jung et al., 2010a). Further-
more, Rh1 inhibits the phosphorylation of JAK1, STAT1, STAT3,
and ERK, which are upstream signaling molecules for IFN-γ-
induced iNOS gene expression. This study also demonstrates that
Rh1 inhibits IFN-γ-induced JAK/STAT and ERK signaling path-
ways and downstream transcription factors, and thereby iNOS
gene expression.
Tumor promotion often accompanies an elevated ornithine
decarboxylase (ODC) activity, acute inﬂammation and induction
of COX-2 activity. Compound K, when applied topically onto
shaven backs of female ICR mice leads to the inhibition of the
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FIGURE 6 | SignalTransduction pathways targeted by selected ginsenosides.
12-O-tetradecanoylphorbol-13-acetate (TPA) induced expression
of COX-2 and production of prostaglandin E2 (Lee et al., 2005a).
The eukaryotic transcription factor NF-κB has been involved
in intracellular signaling pathways associated with inﬂammation
and carcinogenesis. Compound K has been seen to inhibit the
activation of ERK1/2 and Akt signaling. When compound K is
applied topically prior to TPA, expression and activities of ODC
are inhibited dose-dependently (Lee et al., 2005a). In addition,
compound K given prior to each topical dose of TPA markedly
lowered the number of papillomas in mouse skin induced by
7,12-dimethylbenz(a)anthracene. Thus, COX-2 inhibition is an
essential mechanistic pathway for tumor inhibition by compound
K (Lee et al., 2005a). Rg3 is also shown to inhibit expression of
COX-2 in TPA-stimulated mouse skin. Rg3 also exerts potent
inhibitory effects on the activation of AP-1 responsible for c-jun
and c-fos oncogenic transactivation (Keum et al., 2003). P. noto-
ginseng extracts have been shown to reduce signiﬁcantly the levels
of serum TGF-β1, TNF-α, and IL-6 in a hepatic ﬁbrosis model
(induced by carbon tetrachloride) in Sprague-Dawley rats (Peng
et al., 2009).
INHIBITION OF Wnt/β-CATENIN SIGNALING
Colorectal cancers are mostly initiated by aberrant activation
of the Wnt/β-catenin signaling pathway (Kraus et al., 1994).
The ginsenoside Rg3 has been shown to inhibit cell prolifera-
tion and viability of cancer cells in vitro by blocking nuclear
translocation of the β-catenin protein and hence inhibiting β-
catenin/Tcf transcriptional activity. Allelic deletion of the onco-
genic β-catenin in HCT116 cells renders the cells more sensitive
to Rg3-induced growth inhibition. In a xenograft colon cancer
model, Rg3 effectively inhibits the growth of tumors derived
from the colon cancer cell line HCT116. Histologic examina-
tion revealed that Rg3 inhibits cancer cell proliferation, decreases
PNCA expression and diminishes nuclear staining intensity of
β-catenin (He et al., 2011).
INHIBITION OF HYPOXIA-INDUCIBLE FACTOR-1
Hypoxia-inducible factor-1 (HIF-1) activates the transcription
of genes that are involved in crucial aspects of cancer biology,
including angiogenesis, cell survival, glucosemetabolismand inva-
sion. Intratumoral hypoxia and genetic alterations can lead to
HIF-1α overexpression, which has been associated with increased
patient mortality in several cancer types. In both Hep3B cancer
and HEK293 immortalized normal cell lines, aqueous extract of
Korean red ginseng (KRGW) attenuates the expression of hypoxia-
induced genes without apparent cytotoxicity (Choi et al., 2011).
Mechanistically, KRGW does not affect the synthesis, degradation,
and translocation of HIF-1 in hypoxia. Interestingly, the authors
found that KRGW represses the transcriptional activity of HIF-
1 by interfering with the dimerization between HIF-1α and aryl
hydrocarbon receptor nuclear translocator.
ACTIVATION OF Nrf2 PATHWAY
Nuclear erythroid 2 p45-related factor 2 (Nrf2) is a redox-sensitive
basic leucine zipper transcription factor involved in the transcrip-
tional regulation of many antioxidant genes. Nrf2 is inhibited in
the cytoplasm by the anchor protein Kelch-like ECH-associated
protein-1 (Keap1), a cytosolic protein that inhibits Nrf2 signaling
by promoting proteasomal degradation of Nrf2. In the presence of
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oxidative stress or chemical inducers, Nrf2 is released from Keap1
inhibition, translocates to the nucleus, and binds to antioxidant
response element (ARE) consensus sequences. Activation of Nrf2
by chemopreventive agents inﬂuences expression of anti-oxidative
phase-I and phase-II enzymes including heme oxygenase-1 (HO-
1), NADPH quinone oxidoreductase-1 (NQO1), and glutathione
(Lee and Johnson, 2004). An aqueous extract of wild ginseng
has been shown to increase expression of GSTA2, GSTA3, and
GSMT2 via an NRF-ARE pathway (Saw et al., 2010). Korean
RGE has been shown induce HO-1 by NRF–ARE pathway in
rat pheocromocytoma cells (Park et al., 2010b). Ginsenoside Rb1
exhibits protection against 6-hydroxydopamine induced oxidative
stress in human neuroblastoma SH-SY5Y cells (Hwang and Hye,
2010).
INHIBITION OF hTERT
The human telomerase reverse transcriptase (hTERT), the active
subunit of telomerase is activated in cancer cells and prevents
telomere shortening, thus inhibiting of apoptotic processes. The
inhibition of hTERT is an additional mechanism by which gin-
senosides can induce cell death in cancer cells. Compound K is
known to inhibit cell proliferation by inducing apoptosis and cell
cycle arrest at the G1 phase (Kang et al., 2005). Compound K treat-
ment reduces telomerase activity and downregulates the (hTERT)
gene, resulting in the decreased expressions of its protein, and of
the c-Myc and Sp1 proteins (transcription factors of hTERT) in
U937 leukemia cells (Kang et al., 2006). Also, the hot water extract
of Korean red ginseng causes signiﬁcant inhibition on the growth
of U937 leukemia cells which is associated with the inhibition of
hTERT expression (Park et al., 2009).
INHIBITION OF MULTIDRUG RESISTANCE
A major difﬁculty in the treatment of human malignancies is
the development of broad anticancer drug resistance by tumor
cells. This phenomenon has been termed “multidrug resistance”
(MDR). Among all ginsenosides, 20(S)-Rg3 is found to have the
most potent inhibitory activity on MDR. Rg3 reverses MDR in
drug-resistant human ﬁbrocarcinoma KBV20C cells speciﬁcally
and effectively in a dose-dependent manner (Park et al., 2005).
Several ginsenosides, including 20(S)-Rh2, have been shown to
inhibit the transport function of P-glycoprotein and increase sen-
sitivity to cancer chemotherapeutics in resistant cells (Li et al.,
2008).
CLINICAL STUDIES
Though many ginsenosides show a clear anticancer activity in can-
cer cell lines or xenograft tumor models, it is imperative to observe
their effects in human subjects. Two Chinese studies have found
that ginseng works synergistically with chemotherapy: One study
examined 176 digestive tract cancer cases and found reduced toxic
effects (Li, 1992). The other study involved a randomized trial
of 63 stomach cancer cases (Lin et al., 1995). Both studies found
improved immune function. Five studies examined the effective-
ness of ginseng in relation to cancer mortality as an end point. Two
were case–control studies (Yun and Choi, 1990; Rebbeck et al.,
2007); two were prospective studies (Yun and Choi, 1998; Cui
et al., 2006) while one was a randomized trial (Suh et al., 2002).
The randomized study conducted in Korea found a 5-year disease
free survival and signiﬁcantly longer survival time among stage III
gastric cancer patients during postoperative chemotherapy.
One of the case–control studies found no signiﬁcant associa-
tion between breast cancer risk and ginseng (Rebbeck et al., 2007).
However, the case control study conducted in a Korean popula-
tion reported a signiﬁcant protective effect against total cancer
risk (Yun and Choi, 1990). Even among subjects who consumed
ginseng only one to three times a year, a protective effect was
found. The protective effect was found among a variety of cancer
types with both cohort studies reporting a signiﬁcant protective
effect.
Overall, fairly consistent protective effect of ginseng has been
found against cancer risk and cancer mortality. Also, an improved
immune function may be possible when ginseng is administered
during chemotherapy. A protective effect might already be pos-
sible with minimal consumption of ginseng (one to three times
a year; Yun and Choi, 1990). However, some of the above stud-
ies (Li, 1992; Lin et al., 1995) used compound Chinese herbal
preparations containing ginseng extracts. It, therefore, becomes
difﬁcult to actually attribute the chemopreventive properties of
the formulation speciﬁcally to a particular class of compounds,
i.e., ginsenosides.
Also, sometimes conﬂicting and confusing results come to the
fore. As an example, a large case–control study and a small cohort
study have both suggested that ginseng use is associated with a
60–70% reduction in gastric cancer risk in Korean populations.
However, when the study was attempted to be duplicated in a
large prospective cohort study of Chinese women, no associa-
tion between ginseng intake and gastric cancer risk was found
(Kamangar et al., 2007).
A randomized, double-blind clinical study to investigate
whether American ginseng might help cancer-related fatigue, sug-
gests that American ginseng, at a dose of 750 mg/day, does not
provide any beneﬁt over that seen with a placebo However, the
twohighest doses of ginseng (1000 and 2000 mg/day) did appear to
decrease fatiguemore than a placebo, asmeasured by various scales
of fatigue, vitality, and well-being. Data suggested that the higher
doses of ginseng might be necessary for alleviating cancer-related
fatigue (Barton et al., 2010).
In a randomized, double-blinded, placebo-controlled trial on
643 chronic atrophic gastritis patients in China, RGE powder was
administered orally to each patient per week for 3 years and fol-
lowed up for 8 years. The development of different types of cancers
in the red ginseng subjects was compared to that of a placebo
group and it was seen that administration of RGE powder for
3 years exerted signiﬁcant preventive effects on the incidence of
non-organ-speciﬁc human cancers in males (Yun et al., 2010).
CONCLUSION
Pre-clinical and clinical studies indicate that ginsenosides can be
effective and safe anticancer agents. Ginsenoside saponins exhibit
diverse molecular mechanisms of action, regulating most known
modulators of carcinogenesis. Because of various mechanisms of
cell death employed by ginsenosides, it may be difﬁcult for cells
to develop resistance to ginsenoside-induced cell death. Further-
more, the ability to kill tumor cells and relative non-toxicity to
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normal cells make ginsenosides attractive candidates for drug
development. However, the diversity in both chemical struc-
ture and biological activity leads to several challenges. Different
species of ginseng have different saponin proﬁles. Also the mode
of preparation of the plant extracts affects the quantity of its
active anticancer principles. For example, heat treated red gin-
seng has a higher quantity of Rg3, Rh2, and PPD. As a result, it
is often difﬁcult to standardize studies and varying results have
been obtained. What is needed today is a systematic study of
a series of related compounds in established, well characterized
cancer models to ascertain the relationship between the structure
and anticancer activity of these compounds. These data should
then be used to develop novel semi-synthetic ginsenosides with
improved efﬁcacy, pharmacokinetics, and bioavailability proﬁles.
The use of modern combinatorial libraries and high throughput
screening techniques coupled with an in-depth understanding of
the molecular mechanisms underlying ginseng’s biological activi-
ties is necessary to harness the full beneﬁts of ginseng and ginseng
products in treatment and prevention of cancer and other chronic
diseases.
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